OA11448A - Novel dihydroxyhexanoic acid derivatives. - Google Patents

Novel dihydroxyhexanoic acid derivatives. Download PDF

Info

Publication number
OA11448A
OA11448A OA1200000214A OA1200000214A OA11448A OA 11448 A OA11448 A OA 11448A OA 1200000214 A OA1200000214 A OA 1200000214A OA 1200000214 A OA1200000214 A OA 1200000214A OA 11448 A OA11448 A OA 11448A
Authority
OA
OAPI
Prior art keywords
amide
dihydroxy
carboxylic acid
benzyl
carbamoyl
Prior art date
Application number
OA1200000214A
Other languages
English (en)
Inventor
Matthew Frank Brown
Christopher Stanley Poss
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11448A publication Critical patent/OA11448A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
OA1200000214A 1998-02-05 2000-07-28 Novel dihydroxyhexanoic acid derivatives. OA11448A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05

Publications (1)

Publication Number Publication Date
OA11448A true OA11448A (en) 2003-11-18

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000214A OA11448A (en) 1998-02-05 2000-07-28 Novel dihydroxyhexanoic acid derivatives.

Country Status (37)

Country Link
EP (1) EP1051405B1 (es)
JP (1) JP3693916B2 (es)
KR (1) KR100385529B1 (es)
CN (1) CN1177834C (es)
AP (1) AP992A (es)
AR (1) AR016175A1 (es)
AT (1) ATE337307T1 (es)
AU (1) AU752407B2 (es)
BG (1) BG104726A (es)
BR (1) BR9907655A (es)
CA (1) CA2320388C (es)
DE (1) DE69932920T2 (es)
DZ (1) DZ2717A1 (es)
EA (1) EA003137B1 (es)
ES (1) ES2268847T3 (es)
GT (1) GT199900011A (es)
HK (1) HK1034969A1 (es)
HR (1) HRP20000529B1 (es)
HU (1) HUP0100832A3 (es)
IL (1) IL137330A0 (es)
IS (1) IS5562A (es)
MA (1) MA26603A1 (es)
MY (1) MY133125A (es)
NO (1) NO20003965D0 (es)
NZ (1) NZ505724A (es)
OA (1) OA11448A (es)
PA (1) PA8467301A1 (es)
PE (1) PE20000243A1 (es)
PL (1) PL342817A1 (es)
SK (1) SK11262000A3 (es)
TN (1) TNSN99013A1 (es)
TR (1) TR200002248T2 (es)
TW (1) TW470744B (es)
UA (1) UA57824C2 (es)
WO (1) WO1999040061A2 (es)
YU (1) YU47100A (es)
ZA (1) ZA99873B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535358A (ja) * 1999-01-29 2002-10-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 移植片拒絶反応及び虚血−再灌流障害の予防方法
CA2376275A1 (en) * 1999-08-20 2001-03-01 Michael John Ricks Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
KR20020072304A (ko) * 2000-02-04 2002-09-14 화이자 프로덕츠 인코포레이티드 헤테로사이클릭 아미드 유도체
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
ATE486586T1 (de) 2001-06-22 2010-11-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
CA2484342A1 (en) * 2002-05-14 2003-11-20 Pfizer Products Inc. Methods for manufacture of dihydro-furan-2-one derivatives
CA2484860A1 (en) * 2002-05-14 2003-11-20 Pfizer Products Inc. Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making
OA12894A (en) * 2002-08-12 2006-10-13 Pfizer Prod Inc Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoy 1-1-(3-fluorobenzyl)-2,7-dihydroxy-7-met hyl-octyl]-amide.
AU2003249474A1 (en) 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
DE69527405T2 (de) * 1994-10-19 2003-03-13 Novartis Ag, Basel Antivirale Ether von Aspartat-Protease-Substrat-Isosteren
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
JP3693916B2 (ja) 2005-09-14
AP992A (en) 2001-08-06
AU752407B2 (en) 2002-09-19
CA2320388C (en) 2005-05-03
IL137330A0 (en) 2001-07-24
NZ505724A (en) 2003-02-28
KR20010040684A (ko) 2001-05-15
PA8467301A1 (es) 2000-05-24
CN1177834C (zh) 2004-12-01
DE69932920D1 (de) 2006-10-05
GT199900011A (es) 2000-07-20
PL342817A1 (en) 2001-07-02
NO20003965D0 (no) 2000-08-04
MA26603A1 (fr) 2004-12-20
HK1034969A1 (en) 2001-11-09
JP2002502839A (ja) 2002-01-29
AR016175A1 (es) 2001-06-20
EP1051405B1 (en) 2006-08-23
HUP0100832A3 (en) 2002-03-28
EP1051405A2 (en) 2000-11-15
MY133125A (en) 2007-10-31
NO20003965L (es) 2000-10-03
ZA99873B (en) 2000-08-04
AP9901457A0 (en) 1999-03-31
SK11262000A3 (sk) 2001-01-18
WO1999040061A2 (en) 1999-08-12
HRP20000529A2 (en) 2001-08-31
BG104726A (en) 2001-04-30
CN1290255A (zh) 2001-04-04
IS5562A (is) 2000-07-14
TR200002248T2 (tr) 2000-12-21
CA2320388A1 (en) 1999-08-12
HRP20000529B1 (en) 2004-12-31
HUP0100832A2 (hu) 2002-02-28
KR100385529B1 (ko) 2003-05-27
YU47100A (sh) 2002-11-15
AU1778999A (en) 1999-08-23
EA003137B1 (ru) 2003-02-27
WO1999040061A3 (en) 1999-10-21
TNSN99013A1 (fr) 2005-11-10
UA57824C2 (uk) 2003-07-15
BR9907655A (pt) 2000-10-24
DE69932920T2 (de) 2007-02-08
ES2268847T3 (es) 2007-03-16
DZ2717A1 (fr) 2003-09-01
PE20000243A1 (es) 2000-04-07
TW470744B (en) 2002-01-01
EA200000741A1 (ru) 2001-02-26
ATE337307T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
AP992A (en) Novel dihydroxyhexanoic acid derivatives.
EP0966443B1 (en) Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
EP2970336B1 (en) Tetrahydropyrrolothiazine compounds
EP3160948B1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
JPH10509150A (ja) 酸化窒素シンターゼ阻害剤としてのサイクリックアミジンアナログ
WO2005058891A1 (de) Pyrrolopyridin-substituierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
SK1852004A3 (sk) Deriváty piperazínu s účinkami antagonistu receptora CCR1
CZ236595A3 (en) Amide derivatives of 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxyalkanoic acids
WO2023057414A1 (en) Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
KR930007431B1 (ko) 경구용 활성 레닌 억제제
CA2028530A1 (en) Substituted pyrimidobenzimidazole derivatives
WO2008134228A1 (en) Benzoxazole compounds
US6673801B1 (en) Dihydroxyhexanoic acid derivatives
NZ523610A (en) A method of treating inflammatory conditions in a non-human mammal comprising administration of dihydroxyhexanoic acid derivatives
Nilsson et al. Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl) acetamide
MXPA00007690A (es) Nuevos derivados del acido dihidroxihexanoico
US6858744B2 (en) Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
CZ20002760A3 (cs) Nové deriváty dihydroxyhexanové kyseliny a farmaceutický prostředek, který je obsahuje
US20040049057A1 (en) Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
US20040087797A1 (en) Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
EP0720988A1 (de) Neue Pseudopeptide mit Trifluormethyl-substituiertem 2-Azabicyclooctan